- Home
- HCM vs PK Comparison
HCM vs PK Comparison
Compare HCM & PK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- PK
- Stock Information
- Founded
- HCM 2000
- PK 1946
- Country
- HCM Hong Kong
- PK United States
- Employees
- HCM N/A
- PK N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- PK Real Estate Investment Trusts
- Sector
- HCM Health Care
- PK Real Estate
- Exchange
- HCM Nasdaq
- PK Nasdaq
- Market Cap
- HCM 2.5B
- PK 2.1B
- IPO Year
- HCM N/A
- PK N/A
- Fundamental
- Price
- HCM $17.59
- PK $11.53
- Analyst Decision
- HCM Buy
- PK Hold
- Analyst Count
- HCM 2
- PK 11
- Target Price
- HCM $23.50
- PK $12.85
- AVG Volume (30 Days)
- HCM 60.7K
- PK 3.5M
- Earning Date
- HCM 08-07-2025
- PK 07-31-2025
- Dividend Yield
- HCM N/A
- PK 12.49%
- EPS Growth
- HCM N/A
- PK 45.67
- EPS
- HCM 0.04
- PK 0.61
- Revenue
- HCM $630,201,000.00
- PK $2,602,000,000.00
- Revenue This Year
- HCM $14.86
- PK $2.45
- Revenue Next Year
- HCM $19.54
- PK $2.92
- P/E Ratio
- HCM $77.78
- PK $18.40
- Revenue Growth
- HCM N/A
- PK N/A
- 52 Week Low
- HCM $11.51
- PK $8.27
- 52 Week High
- HCM $21.50
- PK $16.23
- Technical
- Relative Strength Index (RSI)
- HCM 66.22
- PK 54.34
- Support Level
- HCM $15.95
- PK $10.65
- Resistance Level
- HCM $17.97
- PK $10.92
- Average True Range (ATR)
- HCM 0.32
- PK 0.29
- MACD
- HCM 0.14
- PK -0.02
- Stochastic Oscillator
- HCM 83.59
- PK 38.19
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.